Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Myelodysplastic syndromes (MDS) are heterogeneous neoplastic disorders of hematopoietic stem cells (HSCs). The current standard of care for patients with MDS is hypomethylating agent (HMA)-based therapy; however, almost 50% of MDS patients fail HMA therapy and progress to acute myeloid leukemia, fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganan-Gomez, Irene, Yang, Hui, Ma, Feiyang, Montalban-Bravo, Guillermo, Thongon, Natthakan, Marchica, Valentina, Richard-Carpentier, Guillaume, Chien, Kelly, Manyam, Ganiraju, Wang, Feng, Alfonso, Ana, Chen, Shuaitong, Class, Caleb, Kanagal-Shamanna, Rashmi, Ingram, Justin P., Ogoti, Yamini, Rose, Ashley, Loghavi, Sanam, Lockyer, Pamela, Cambo, Benedetta, Muftuoglu, Muharrem, Schneider, Sarah, Adema, Vera, McLellan, Michael, Garza, John, Marchesini, Matteo, Giuliani, Nicola, Pellegrini, Matteo, Wang, Jing, Walker, Jason, Li, Ziyi, Takahashi, Koichi, Leverson, Joel D., Bueso-Ramos, Carlos, Andreeff, Michael, Clise-Dwyer, Karen, Garcia-Manero, Guillermo, Colla, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938266/
https://www.ncbi.nlm.nih.gov/pubmed/35241842
http://dx.doi.org/10.1038/s41591-022-01696-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938266/
https://www.ncbi.nlm.nih.gov/pubmed/35241842
http://dx.doi.org/10.1038/s41591-022-01696-4

Ejemplares similares